Breast cancer metastatic
Not recruitingStudy of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
- Disease:Breast cancer metastatic
- Substances:FulvestrantInavolisib+1
Belgium- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
- Sponsor:F. Hoffmann-La Roche AG















